Corporate presentation highlights Halneuron program and interim data
Dogwood highlighted Halneuron injection, a tetrodotoxin-based Nav1.7 blocker, as its lead non-opioid program for chemotherapy-induced neuropathic pain.
Phase 2b HALT-CINP-203 final data remain projected for fall 2026; interim analysis set sample size at 210-240 patients for 80%-85% power.
Interim results in 97 patients showed a treatment effect versus placebo, including a durable response pattern in refractory patients; dropouts about 4.4%.
Pro forma cash was USD 13.2 million as of March 31, 2026; shares outstanding were 33,553.
DWTX•
